(Albany, US), November 09, 2026 – DelveInsight’s “Obesity Pipeline Insight 2026” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the obesity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space.
Download DelveInsight’s comprehensive Obesity Pipeline Report to explore emerging therapies @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight
Key Takeaways from the Obesity Pipeline Report
Access DelveInsight’s in-depth pipeline Analysis for a closer look at promising breakthroughs @ Obesity Clinical Trials and Studies
The Obesity Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Obesity Pipeline Report also highlights the unmet needs with respect to the Obesity.
Obesity Overview
Obesity is a chronic, relapsing, adiposity-based disease characterized by excessive or abnormal body fat that can impair physical health and increase morbidity and mortality. Traditionally, obesity in adults is defined using BMI 30 kg/m², although newer frameworks emphasize that BMI alone does not capture fat distribution or obesity-related organ dysfunction. Central adiposity, excess body fat and associated complications are increasingly incorporated into diagnosis. Common signs and symptoms include excess body weight, increased waist circumference, breathlessness, fatigue, reduced physical mobility, joint discomfort and sleep disturbances. Obesity is multifactorial and results from interactions among genetic susceptibility, energy imbalance, dietary patterns, physical inactivity, environmental factors, medications, socioeconomic conditions and neuroendocrine regulation.
Obesity Emerging Drugs Profile
Retatrutide is an investigational once-weekly injectable triple agonist developed by Eli Lilly that simultaneously activates the GIP, GLP-1, and glucagon receptors for the treatment of obesity. It is designed to promote weight loss through complementary effects on appetite, glucose metabolism, and energy expenditure. In Phase III obesity trials, retatrutide demonstrated significant reductions in body weight and HbA1c, with results supporting its continued development as a potential treatment for obesity and related metabolic conditions. Retatrutide remains investigational and is not yet approved for obesity. Currently, the drug is in Phase III of its development for the treatment of Obesity.
Enicepatide (CT-388) is an investigational once-weekly subcutaneous dual GLP-1/GIP receptor agonist being developed by Roche for chronic weight management in people with obesity or overweight. It is designed to activate both GLP-1 and GIP receptors while minimising ?-arrestin recruitment, potentially enabling sustained receptor activity. Enicepatide has demonstrated significant weight-loss effects in Phase II studies, including up to 22.7% mean body-weight reduction at 48 weeks at the highest dose. It is currently being evaluated in Phase III in adults with obesity or overweight, with or without type 2 diabetes.
KDS2010 is an investigational reversible monoamine oxidase-B (MAO-B) inhibitor being developed by NeuroBiogen for the treatment of obesity. It is designed as an oral, once-daily therapy, with the potential to address obesity through a mechanism distinct from incretin-based treatments. KDS2010 is being evaluated for its effects on body weight, body composition, metabolic parameters, and MAO-B activity. The ongoing Phase IIa study is assessing 120 mg, 180 mg, and 240 mg doses in adults with overweight or obesity. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Obesity.
WVE-007 is an investigational INHBE-targeting GalNAc-siRNA therapy developed by Wave Life Sciences for the treatment of obesity and cardiometabolic diseases. It is designed to silence INHBE mRNA, thereby reducing Activin E signaling and promoting fat loss while preserving lean muscle mass. WVE-007 is administered by subcutaneous injection and has demonstrated reductions in visceral and total body fat in early clinical studies. The ongoing Phase I/IIa INLIGHT trial is evaluating its safety, pharmacokinetics, pharmacodynamics, and effects on body composition and weight in adults with overweight or obesity. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Obesity.
ASC36 is an investigational next-generation amylin receptor peptide agonist being developed by Ascletis Pharma for the treatment of obesity. It is designed as a long-acting injectable therapy, with potential dosing once monthly to once quarterly. By activating amylin receptors, ASC36 is intended to regulate appetite and promote weight loss through effects on satiety and energy balance. In August 2026, Ascletis initiated a Phase I study in the US following FDA clearance of its IND application.
NBIP-‘1968 is an investigational long-acting GLP-1/GIP/glucagon receptor triple agonist being developed by Neurocrine Biosciences for the treatment of obesity. It is designed for once-weekly subcutaneous administration, simultaneously targeting three complementary metabolic pathways involved in appetite regulation, energy balance, and glycemic control. The candidate incorporates balanced glucagon receptor activity with the aim of maximizing metabolic benefits while supporting tolerability. In August 2026, Neurocrine initiated a Phase I first-in-human study to evaluate its safety and tolerability in ad ults with varying BMI categories. Currently, the drug is in Phase I stage of its development for the treatment of Obesity.
Explore DelveInsight’s expert-driven report today! @ Obesity Unmet Needs
The Obesity pipeline report provides insights into
Obesity Companies
Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, ERX Pharmaceuticals and others.
Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as
Obesity Products have been categorized under various Molecule types such as
Download DelveInsight’s latest report to gain strategic insights into upcoming Obesity Therapies @ Obesity Market Drivers and Barriers, and Future Perspectives
Scope of the Obesity Pipeline Report
Find out in DelveInsight’s exclusive Obesity Pipeline Report @ Obesity Emerging Drugs and Major Companies
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9650213330Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting
